Company news
Biostax Corp. news in 2016
Biostax Corp.'s news releases, calls and decks from 2016, newest first.
Immune Therapeutics Statement on the Death of Christopher Pearce, Founder and Chief Operating Officer
December 12, 2016
Immune Therapeutics Redeems $656,250 Convertible Note; Company Actively Working to Strengthen Balance Sheet by Year End
November 15, 2016
Immune Therapeutics Announces Filing Acceptance of New Drug Applications for Lodonal™ for the Treatment of Patients with Human Immuno-Deficiency, Cancer and as an Immune Booster
October 26, 2016
Immune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board
September 22, 2016
Immune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer
August 23, 2016
Immune Therapeutics, Inc. to Hold an Informational Shareholder Meeting on Wednesday, August 17, 2016 at 10 A.M. EDT
July 26, 2016
Immune Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
June 15, 2016
Lodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World's Leading Health Forums
May 19, 2016
Lodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World’s Leading Health Forums
May 18, 2016
Immune Therapeutics Receives NAFDAC Approval for Lodonal(TM) in Nigeria: Approval Follows Successful Recent Bridging Study
April 27, 2016
Immune Therapeutics Signs Binding Letter of Intent to Acquire Chinese CAR-T Technology and Clinical Data
April 21, 2016
Immune Therapeutics, Inc. Provides Drug Development Program Status Update on Methionine-Enkelphine ("MENK") in China
April 11, 2016
Immune Therapeutics, Inc., Appoints Two New Board Members
March 3, 2016
Fidson Healthcare Plc and GB Pharma Holdings position pharmaceutical outreach into Nigeria and Beyond!
January 27, 2016